PMID: 19457666
Tice CM, Xu Z, Yuan J, Simpson RD, Cacatian ST, Flaherty PT, Zhao W, Guo J, Ishchenko A, Singh SB, Wu Z, Scott BB, Bukhtiyarov Y, Berbaum J, Mason J, Panemangalore R, Cappiello MG, Muller D, Harrison RK, McGeehan GM, Dillard LW, Baldwin JJ, Claremon DA
Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.
Bioorg Med Chem Lett. 2009 Jul 1;19(13):3541-5. Epub 2009 May 5.
Structure-based drug design led to the identification of a novel class of potent, low MW alkylamine renin inhibitors. Oral administration of lead compound 21l, with MW of 508 and IC(50) of 0.47nM, caused a sustained reduction in mean arterial blood pressure in a double transgenic rat model of hypertension.